Compare MakeMyTrip Ltd (MMYT) vs Novartis AG (NVS) Price & Performance

MMYT trades at $44.06, up 1.5% with bearish technical signals but strong analyst support. The company reported $978M revenue and $95M net income for 2025, though earnings have been mixed with two recent misses. Valuation metrics show high P/E of 189 but solid gross margins of 73%. Technical indicators show oversold conditions with RSI at 25.31, while institutional sentiment remains positive with 72.7% buy ratings and $77 consensus target.

The stock presents a divergence between technical weakness and fundamental optimism. Upside potential exists from the 75% analyst price target premium and planned Indian listing, but risks include volatile earnings performance, rising debt-to-asset ratio projection to 79.9%, and competitive travel sector pressures. Current levels near support at $42-43 may offer entry points for long-term investors.

Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.

The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.